Cargando…
ADAM17 inhibition enhances platinum efficiency in ovarian cancer
Chemotherapeutic resistance evolves in about 70 % of ovarian cancer patients and is a major cause of death in this tumor entity. Novel approaches to overcome these therapeutic limitations are therefore highly warranted. A disintegrin and metalloprotease 17 (ADAM17) is highly expressed in ovarian can...
Autores principales: | Hedemann, Nina, Rogmans, Christoph, Sebens, Susanne, Wesch, Daniela, Reichert, Manuel, Schmidt-Arras, Dirk, Oberg, Hans-Heinrich, Pecks, Ulrich, van Mackelenbergh, Marion, Weimer, Jörg, Arnold, Norbert, Maass, Nicolai, Bauerschlag, Dirk O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882316/ https://www.ncbi.nlm.nih.gov/pubmed/29662625 http://dx.doi.org/10.18632/oncotarget.24682 |
Ejemplares similares
-
ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids
por: Hedemann, Nina, et al.
Publicado: (2021) -
Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer
por: Hugendieck, Gerrit, et al.
Publicado: (2023) -
ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer
por: Rogmans, Christoph, et al.
Publicado: (2021) -
High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021) -
Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
por: Oberg, Hans‐Heinrich, et al.
Publicado: (2019)